Novo Nordisk's Wegovy weight loss drug wins UK approval for use as a heart treatment
The U.K.'s health regulator on Tuesday approved the use of Novo Nordisk's Wegovy weight loss drug to reduce the risk of overweight and obese adults suffering from serious heart problems or strokes. It follows similar label expansion by the U.S. Food and Drug Administration in March.
Novo Nordisk's Wegovy gets UK approval for lowering heart risks
Novo Nordisk's weight-loss drug Wegovy has secured the UK regulator's approval for its use to reduce the risk of overweight and obese adults suffering serious heart problems or strokes, the agency said on Tuesday.
Wegovy-maker Novo Nordisk buys land in Denmark for potential new production plant
Novo Nordisk , the maker of weight-loss drug Wegovy, has bought a site in Denmark's third largest city Odense and begun preparatory excavation works for a potential new production plant, it said on Tuesday,
Novo Nordisk Faces Setback in Netherlands Over Wegovy Insurance Coverage
The famed Danish drug maker Novo Nordisk A/S NVO expressed disappointment on Wednesday following a recommendation by the Dutch Health Care Institute advising the Netherlands government against including the company's popular weight-loss drug, Wegovy, in the basic insurance coverage.
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
In the most recent trading session, Novo Nordisk (NVO) closed at $140.87, indicating a -0.37% shift from the previous trading day.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novo Nordisk investor backs $100m Alzheimer's funding round
Novo Holdings, the main shareholder of Novo Nordisk (NYSE:NVO), has led a $100 million Series C funding round for Swiss company Asceneuron, which is developing a next-generation treatment for Alzheimer's. ASN51 is an oral small molecule drug targeting intracellular tau, protein tangles inside nerve cells, which could potentially revolutionize Alzheimer's treatment, according to Novo's senior partner Naveed Siddiqi.
Novo Nordisk (NVO) GLP-1 Drug Regarded Safe for Brain by Oxford
Oxford study demonstrates that Novo Nordisk's (NVO) semaglutide is not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications over one year.
Here's 80 Billion More Reasons to Buy Novo Nordisk Stock
Novo Nordisk is already developing its next set of weight loss therapies. At least one market research firm is incredibly optimistic about its prospects.
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market
Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the country, two sources familiar with the meeting told Reuters.
Ozempic linked with lower dementia risk, nicotine use, British study finds
Novo Nordisk's popular diabetes treatment Ozempic could be tied to a lower risk of cognitive problems, according to an observational study published by researchers at Oxford University.
Novo Nordisk Gains as Ozempic Found To Lower Dementia Rates
American depositary receipts (ADRs) of Novo Nordisk (NVO) rose in intraday trading Friday after the release of an Oxford study that showed the Danish company's Ozempic diabetes drug was linked to lower rates of dementia and a range of mental problems.
